After Lilly-Kelonia deal, are any in vivo biotechs left to buy?
Eli Lilly’s $7 billion deal for Kelonia Therapeutics on Monday was simply the most recent instance of the sky-high costs that Big Pharmas are prepared to pay for in vivo CAR-T tech. In truth, it was the corporate’s second play for the area this 12 months—having bought Orna Therapeutics for up to $2.4 billion in February. Lilly…